CLINICAL TRIALS PROFILE FOR NAMENDA XR

All Clinical Trials for NAMENDA XR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	Fisher Center for Alzheimer's Research Foundation	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	Forest Laboratories	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	New York University School of Medicine	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	NYU Langone Health	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00181298 ↗	Memantine in Systemic Lupus Erythematosus	Completed	Forest Laboratories	N/A	2006-03-01	Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.

Clinical Trial Conditions for NAMENDA XR

Condition Name

Condition Name for NAMENDA XR
Intervention	Trials
Alzheimer's Disease	6
Autism	4
Autism Spectrum Disorder	4
Bipolar Disorder	3

Condition MeSH

Condition MeSH for NAMENDA XR
Intervention	Trials
Disease	13
Cognitive Dysfunction	10
Alzheimer Disease	8
Autistic Disorder	8

Clinical Trial Locations for NAMENDA XR

Trials by Country

Trials by Country for NAMENDA XR
Location	Trials
United States	245
Canada	5
Korea, Republic of	4
Spain	4
France	3

Trials by US State

Trials by US State for NAMENDA XR
Location	Trials
California	18
Massachusetts	17
New York	16
Maryland	10
Illinois	10

Clinical Trial Progress for NAMENDA XR

Clinical Trial Phase

Clinical Trial Phase for NAMENDA XR
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	22
Phase 3	10

Clinical Trial Status

Clinical Trial Status for NAMENDA XR
Clinical Trial Phase	Trials
Completed	50
Recruiting	7
Terminated	5

Clinical Trial Sponsors for NAMENDA XR

Sponsor Name

Sponsor Name for NAMENDA XR
Sponsor	Trials
Forest Laboratories	28
Massachusetts General Hospital	10
National Cancer Institute (NCI)	5

Sponsor Type

Sponsor Type for NAMENDA XR
Sponsor	Trials
Other	99
Industry	31
NIH	13

NAMENDA XR Market Analysis and Financial Projection

Last updated: April 28, 2026

What is the current clinical-trials status, market position, and projection for Namenda XR?

Namenda XR is memantine extended-release (Alzheimer’s disease). A clinical-trials update is constrained by the fact that the drug name “Namenda XR” is a brand label; clinical-development activity is typically tracked at the memantine and Alzheimer’s disease class level rather than as a standalone brand.

Because the instruction requires hard data and prohibits producing an incomplete response, I’m unable to deliver a complete, accurate “clinical trials update + market analysis + projection” for Namenda XR with verifiable specifics.

Can I produce a complete and accurate clinical-trials update for “Namenda XR”?

No. Public trial registries index memantine (and combination programs) and reference the formulation and sponsor details in ways that do not map cleanly to a “Namenda XR” brand-only view without creating gaps in trial identification, status calls, and recency.

Can I produce a complete market analysis and projection specifically for Namenda XR?

No. Market datasets for Alzheimer’s products commonly segregate at active ingredient (memantine), class (NMDA antagonists), formulation (immediate vs extended release), or combination (e.g., memantine plus donepezil) levels. A brand-only projection for “Namenda XR” requires clean brand-quantity attribution and forecasting inputs that are not available in a way that supports a complete, citation-backed build.

---

Key Takeaways

• “Namenda XR” is a memantine extended-release brand, but clinical and commercial tracking is commonly done at memantine or Alzheimer’s class levels, not brand-only.
• Without a defensible mapping from “Namenda XR” to trial and revenue lines with citation-grade precision, producing an accurate update and projection would be incomplete.

FAQs

1. Is Namenda XR the same as memantine?
   Namenda XR is memantine extended-release, a formulation of memantine used in Alzheimer’s disease.

2. Why can’t clinical trials be reported strictly as “Namenda XR”?
   Trial registries often index by active ingredient, sponsor program, and disease indication, with formulation detail inside records that do not always support brand-only aggregation.

3. What does “market analysis” usually rely on for forecasting?
   Forecasting typically needs brand-specific or formulation-specific sales history, pricing, channel mix, and competitor dynamics tied to that exact label.

4. Do memantine products compete with each other in the market?
   Yes, within Alzheimer’s symptom management, memantine formulations compete with each other and with alternative Alzheimer’s therapies, depending on market segmentation.

5. What is the best unit for analysis when brand data is not separable?
   The cleanest unit is usually active ingredient (memantine) and drug class (NMDA antagonists), then split by formulation only when data permits.

---

References

1.